Fair Value Calculator Fair Value Calculator
EN DE

1187 (1187) Fair Value & Analysis

Healthcare · Market cap HK$7.0B

1 1187 1187 · HK
PriceHK$29.50
Fair ValueHK$36.36
Upside+23.3%
Quality70/100
Evidence: High Range HK$27.27 – HK$45.46

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price +2.8% over the past month.

Price vs Fair Value (2 months)

HK$38.90 HK$26.32 Fair Value HK$36.36 May 2026 Jun 2026

2‑month range HK$26.32 – HK$38.90 · fair‑value band HK$27.27 – HK$45.46 · the HK$29.50 price screens below the HK$36.36 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1187 (1187) currently trades at HK$29.50, while our model-based Fair Value estimate is HK$36.36 — implying the stock looks roughly 23.3% undervalued today. We read business quality at 70/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 1187 generated revenue of HK$3.7B at a net margin of 10.6%. Revenue grew 37.2% year over year. It earns a return on equity of 8.0%. The stock trades on a trailing P/E of 13.6. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$3.7B
Revenue growth (YoY) +37.2%
Net margin 10.6%
Return on equity 8.0%
Free cash flow HK$518M FY2025
P/E ratio 13.6
More key figures
Operating margin 13.3%
EPS growth (YoY) +15.9%

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2025 · reported fiscal years

1187 reported revenue of HK$3.4B in FY2025 versus HK$3.0B in FY2022, a compound +4.4%/yr. Reported net income was HK$372M in FY2025, compounding +7.2%/yr from FY2022.

Revenue +4.4%/yr
FY22 HK$3.0B
FY23 HK$2.9B
FY24 HK$3.0B
FY25 HK$3.4B
Net income +7.2%/yr
FY22 HK$302M
FY23 HK$254M
FY24 HK$312M
FY25 HK$372M

Is 1187 fairly valued? → Check now

Similar stocks

6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock Price Fair Value vs Fair Value
ABT ABT 1,600 MXN 1,231 MXN -23%
Abbott Laboratories, ABTT34 R$39.41 R$30.42 -23%
Stryker Corporation S1YK34 R$79.21 R$43.74 -45%
Medtronic plc MDT $81.67 $60.02 -27%
Boston Scientific Corporation B1SX34 R$229.30 R$43.33 -81%
Edwards Lifesciences Corporation EW $85.98 $41.02 -52%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 1187 (1187) undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$36.36 versus a price of HK$29.50 — about +23% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 1187?
Our model-based fair value for 1187 is HK$36.36 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$29.50.
What is the quality score of 1187?
1187 has a Quality Score of 70/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 1187 (1187)?
1187 reported trailing-twelve-month revenue of about HK$3.7B (latest available figure, as of Jul 2, 2026).
What is the net profit margin of 1187?
The net profit margin of 1187 is about 10.6%, meaning it keeps roughly 10.6% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.